Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment

NCT02628600 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT02628600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment
Lead sponsor
Insmed Incorporated
Phase
Phase 3
Overall status
Completed
Start date
February 5, 2016
Completion date
October 17, 2018
Enrollment
163 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ntm lung infection due to mac